Inclusion Criteria:

- 1. Histologically or cytologically confirmed pheochromocytoma or extra-adrenal
paraganglioma or carcinoid

- 2. Local, locally-advanced or metastatic disease documented as having shown
progression on a scan (CT, MRI, MIBI scan) taken 2 to 12 months prior to baseline
compared to a previous scan taken at any time in the past. Progression must be
documented according to RECIST criteria.

- 3. Disease that is not amenable to surgery, radiation or combined modality therapy
with curative intent.

- 4. Presence of at least one measurable target lesion for further evaluation according
to RECIST criteria

- 5. 18 years or older

- 6. ECOG performance status 0, 1

- 7. Previous treatment with chemotherapy, loco-regional therapy (e.g
chemoembolization) are permitted providing that toxicity has resolved to ≤grade 1 at
study entry and that last treatment was at least 4 weeks prior to baseline
assessment.

- 8. Adequate organ function

- 9. A patient with the willingness to comply with the study protocol during the study
period and capable of complying with it

- 10. A patient who signed the informed consent prior to the participation of the study
and who understands that he/she has a right to withdrawal from participation in the
study at any time without any disadvantages.

Exclusion Criteria:

- 1. A patient with no measurable disease

- 2. Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study
entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to
study entry)

- 3. A patient with functioning carcinoid

- 4. A patient with previous active or passive immunotherapy

- 5. A patient with intestinal obstruction or impending obstruction, recent active
upper GI bleeding

- 6. A pregnant or lactating patient

- 7. A patient of childbearing potential without being tested for pregnancy at baseline
or with being tested for positive. (A postmenopausal woman with the amenorrhea period
of at least 12 months or longer is considered to have non-childbearing potential)

- 8. A man or woman of childbearing potential who has no willingness to use a
contraceptive measure during the study

- 9. A patient with history of another malignant disease within past 5 years, except
curatively treated basal cell carcinoma of skin and cervical carcinoma in situ.

- 10. A patient with history of uncontrolled seizures, central nervous system disorder
or psychiatric disorders that are considered clinically significant by the
investigator that would prohibit the understanding of informed consent or that may be
considered to interfere with the compliance of the administration of the study
medications.

- 11. A patient with clinically significant heart disease (e.g. congestive heart
failure, symptomatic coronary artery diseases, cardiac arrhythmia, etc) or myocardial
infarction within past 12 months.

- 12. Ongoing cardiac arrhythmia of grade ≥2, atrial fibrillation of any grade, or QTc
interval>450msec for males or >470msec for female.

- 13. A patient with interstitial pneumonia or diffuse symptomatic fibrosis of the
lungs

- 14. A patient with peripheral neuropathy of grade 1 by NCI CTC, caused by other
factors (e.g. alcohol, diabetes, etc). If the absence of deep tendon reflexes is the
only neurologic disorder, this condition does not apply to the exclusion criteria.

- 15. A patient with organ transplantation requiring immunosuppressive therapy